Repligen Corporation (RGEN)
Makes equipment and chemicals that help pharmaceutical companies manufacture biological drugs.
$150.30+0.15%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+26.4%
The outlook
Repligen is trading well above its key moving averages and sits about two-thirds of the way up its 52-week range. Analyst consensus is strongly positive, with an average price target around 18% above the current price. The stock carries a notably elevated valuation at 167x trailing earnings.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 20 analysts
Price trendAbove its 50- & 200-day averages
52-week range66% of the way from its 52-week low to high
Price targetAvg target +18% vs current price
Analyst price target
~12-month · 20 analysts$178.05average target+18.5% vs now
Now $150.30
Low $142.00High $220.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.48B
52-wk high
$175.77
52-wk low
$100.99
50-day avg
$130.63
200-day avg
$139.87
Trailing P/E
167.0